BHCM
CTKB icon

Brevan Howard Capital Management’s Cytek Biosciences CTKB Stock Holding History

Brevan Howard Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.2K Buy
+10,438
New +$44.6K ﹤0.01% 2020
2025
Q4 		– Sell
-47,480
Closed -$165K – 1894
2025
Q3 		$165K Sell
47,480
-7,642
-14% -$28.7K ﹤0.01% 1793
2025
Q2 		$187K Sell
55,122
-24,832
-31% -$82.8K ﹤0.01% 1724
2025
Q1 		$321K Buy
+79,954
New +$414K ﹤0.01% 846

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Brevan Howard Capital Management's CTKB Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 10,438 shares worth $46.2K. The stake represents ﹤0.01% of the portfolio and ranks #2020 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in CTKB as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in CTKB in Q1 2025 and has held it in 4 quarters since. The position peaked at $321K in Q1 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Brevan Howard Capital Management held 10,438 shares of Cytek Biosciences worth $46.2K as of Q2 2026.
  • Cytek Biosciences was a new Brevan Howard Capital Management position in Q2 2026.
  • Cytek Biosciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #2020 holding.
  • Brevan Howard Capital Management first reported a position in Cytek Biosciences in Q1 2025 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Cytek Biosciences position peaked at $321K in Q1 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.